Apogee Therapeutics, Inc. (APGE) Financial Statements
Apogee Therapeutics financial statements at a glance
Apogee Therapeutics reported revenue of $0 for fiscal year 2025 (ended December 31, 2025). Net income was -$255.84 million.
At the end of fiscal year 2025 it had total assets of $937.13 million, total liabilities of $33.25 million and shareholders' equity of $903.88 million, with cash and short-term investments of $730.19 million and total debt of $8.85 million.
Its operations brought in -$227.45 million of cash; capital spending was $5.15 million, leaving free cash flow of -$232.60 million.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 4 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.
Apogee Therapeutics, Inc.
Income Statement
Annual • USD
Apogee Therapeutics key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue | $0 | – | – | – |
| Operating income | -$285.6M | -$216.9M | -$93.0M | -$30.7M |
| Net income | -$255.8M | -$182.1M | -$84.0M | -$39.8M |
| Diluted EPS | – | – | -$3.36 | -$1.46 |
| Total assets | $937.1M | $754.0M | $401.4M | $152.1M |
| Total liabilities | $33.3M | $37.2M | $21.5M | $10.0M |
| Shareholders' equity | $903.9M | $1.0B | $503.4M | $142.1M |
| Cash and short-term investments | $730.2M | $520.7M | $395.5M | $151.9M |
| Total debt | $8.8M | $11.8M | $2.0M | – |
| Operating cash flow | -$227.5M | -$171.2M | -$74.8M | -$16.4M |
| Capital spending | $5.1M | $1.2M | $167,000 | – |
| Free cash flow | -$232.6M | -$172.3M | -$74.9M | -$16.4M |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2022.
Questions and answers
What was Apogee Therapeutics's revenue in fiscal year 2025?
$0.
How much profit does Apogee Therapeutics make?
Apogee Therapeutics reported net income of -$255.84 million for fiscal year 2025; operating income was -$285.60 million.
How much cash and debt does Apogee Therapeutics have?
At the end of fiscal year 2025: cash and short-term investments of $730.19 million and total debt of $8.85 million.
What is Apogee Therapeutics's free cash flow?
-$232.60 million in fiscal year 2025 (operating cash flow of -$227.45 million minus capital spending of $5.15 million).
